|
US4711955A
(en)
|
1981-04-17 |
1987-12-08 |
Yale University |
Modified nucleotides and methods of preparing and using same
|
|
CA1223831A
(en)
|
1982-06-23 |
1987-07-07 |
Dean Engelhardt |
Modified nucleotides, methods of preparing and utilizing and compositions containing the same
|
|
DE3538677A1
(de)
|
1985-10-31 |
1987-05-07 |
Schloemann Siemag Ag |
Wendehaspel
|
|
ATE239484T1
(de)
|
1991-10-24 |
2003-05-15 |
Isis Pharmaceuticals Inc |
Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
|
|
US5792608A
(en)
|
1991-12-12 |
1998-08-11 |
Gilead Sciences, Inc. |
Nuclease stable and binding competent oligomers and methods for their use
|
|
NL9201440A
(nl)
|
1992-08-11 |
1994-03-01 |
Univ Leiden |
Triantennaire clusterglycosiden, hun bereiding en toepassing.
|
|
KR100281163B1
(ko)
*
|
1992-11-06 |
2001-04-02 |
더블류. 하링 |
비형 간염 표면 항원에 대해 활성적인 인체 단일클론 항체의 제조방법
|
|
US20040157780A1
(en)
|
1993-11-29 |
2004-08-12 |
Epimmune Inc. |
CTL inducing peptides from c-erb2 (HER-2/neu)
|
|
WO1995027072A1
(en)
|
1994-04-05 |
1995-10-12 |
Pharmagenics, Inc. |
Determination and identification of active compounds in a compound library
|
|
US5525711A
(en)
|
1994-05-18 |
1996-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pteridine nucleotide analogs as fluorescent DNA probes
|
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
|
DE69829760T3
(de)
|
1997-09-12 |
2016-04-14 |
Exiqon A/S |
Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
|
|
KR100573231B1
(ko)
|
1999-02-12 |
2006-04-24 |
상꾜 가부시키가이샤 |
신규 뉴클레오시드 및 올리고뉴클레오티드 유사체
|
|
AU776362B2
(en)
|
1999-05-04 |
2004-09-09 |
Roche Innovation Center Copenhagen A/S |
L-ribo-LNA analogues
|
|
US6617442B1
(en)
|
1999-09-30 |
2003-09-09 |
Isis Pharmaceuticals, Inc. |
Human Rnase H1 and oligonucleotide compositions thereof
|
|
WO2003022987A2
(en)
|
2001-07-26 |
2003-03-20 |
Eos Biotechnology, Inc. |
Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
|
|
US8090542B2
(en)
*
|
2002-11-14 |
2012-01-03 |
Dharmacon Inc. |
Functional and hyperfunctional siRNA
|
|
EP2752488B1
(en)
|
2002-11-18 |
2020-02-12 |
Roche Innovation Center Copenhagen A/S |
Antisense design
|
|
US20060257851A1
(en)
|
2002-11-26 |
2006-11-16 |
Itzhak Bentwich |
Bioinformatically detectable group of novel viral regulatory genes and uses thereof
|
|
DK2270162T3
(en)
|
2003-06-12 |
2019-01-21 |
Alnylam Pharmaceuticals Inc |
PRESERVED HBV AND HCV SEQUENCES USED FOR GEN-SILENCING
|
|
US7374927B2
(en)
|
2004-05-03 |
2008-05-20 |
Affymetrix, Inc. |
Methods of analysis of degraded nucleic acid samples
|
|
AU2005248147A1
(en)
|
2004-05-11 |
2005-12-08 |
Alphagen Co., Ltd. |
Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
|
|
US20060263798A1
(en)
|
2005-02-11 |
2006-11-23 |
International Business Machines Corporation |
System and method for identification of MicroRNA precursor sequences and corresponding mature MicroRNA sequences from genomic sequences
|
|
WO2007031091A2
(en)
|
2005-09-15 |
2007-03-22 |
Santaris Pharma A/S |
Rna antagonist compounds for the modulation of p21 ras expression
|
|
CA2640171C
(en)
|
2006-01-27 |
2014-10-28 |
Isis Pharmaceuticals, Inc. |
6-modified bicyclic nucleic acid analogs
|
|
US20110177960A1
(en)
|
2006-03-10 |
2011-07-21 |
Ellen Murphy |
Microarray for monitoring gene expression in multiple strains of Streptococcus pneumoniae
|
|
CA3044969A1
(en)
|
2006-05-05 |
2007-12-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gene expression
|
|
JP5441688B2
(ja)
|
2006-05-11 |
2014-03-12 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
５’修飾二環式核酸類似体
|
|
US7666854B2
(en)
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
|
CN101541977A
(zh)
|
2006-09-19 |
2009-09-23 |
诺瓦提斯公司 |
用于raf抑制剂的靶向调节、效力、诊断和/或预后的生物标志物
|
|
DK2092065T4
(da)
|
2006-10-18 |
2019-10-21 |
Ionis Pharmaceuticals Inc |
Antisense-forbindelser
|
|
US8580756B2
(en)
|
2007-03-22 |
2013-11-12 |
Santaris Pharma A/S |
Short oligomer antagonist compounds for the modulation of target mRNA
|
|
EP2170917B1
(en)
|
2007-05-30 |
2012-06-27 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
|
ES2386492T3
(es)
|
2007-06-08 |
2012-08-21 |
Isis Pharmaceuticals, Inc. |
Análogos de ácidos nucleicos bicíclicos carbocíclicos
|
|
CN101796062B
(zh)
|
2007-07-05 |
2014-07-30 |
Isis制药公司 |
6-双取代双环核酸类似物
|
|
JP2010539961A
(ja)
|
2007-10-04 |
2010-12-24 |
サンタリス ファーマ アー／エス |
ＨＩＦ１αの調節のための短いＲＮＡアンタゴニスト化合物
|
|
WO2009067647A1
(en)
|
2007-11-21 |
2009-05-28 |
Isis Pharmaceuticals, Inc. |
Carbocyclic alpha-l-bicyclic nucleic acid analogs
|
|
ES2539026T3
(es)
|
2007-12-27 |
2015-06-25 |
Abbott Laboratories |
Anticuerpos anti-T. cruzi y métodos de uso
|
|
WO2009090182A1
(en)
|
2008-01-14 |
2009-07-23 |
Santaris Pharma A/S |
C4'-substituted - dna nucleotide gapmer oligonucleotides
|
|
WO2009124238A1
(en)
|
2008-04-04 |
2009-10-08 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
|
|
WO2010006111A2
(en)
|
2008-07-10 |
2010-01-14 |
Merck & Co., Inc. |
Methods of using compositions comprising mir-192 and/or mir-215 for the treatment of cancer
|
|
DK2356129T3
(da)
|
2008-09-24 |
2013-05-13 |
Isis Pharmaceuticals Inc |
Substituerede alpha-L-bicykliske nukleosider
|
|
EP2177615A1
(en)
|
2008-10-10 |
2010-04-21 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
|
|
US20100249214A1
(en)
|
2009-02-11 |
2010-09-30 |
Dicerna Pharmaceuticals |
Multiplex dicer substrate rna interference molecules having joining sequences
|
|
CN102325534B
(zh)
|
2008-12-18 |
2016-02-17 |
戴瑟纳制药公司 |
延长的dicer酶底物和特异性抑制基因表达的方法
|
|
WO2011017521A2
(en)
|
2009-08-06 |
2011-02-10 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
|
KR20120095397A
(ko)
|
2009-10-16 |
2012-08-28 |
글락소 그룹 리미티드 |
Ｈｂｖ 안티센스 억제제
|
|
JP2013126374A
(ja)
|
2010-03-04 |
2013-06-27 |
Kyushu Univ |
イソフラボン類の作用に関連する遺伝子
|
|
EP2580228B1
(en)
|
2010-06-08 |
2016-03-23 |
Ionis Pharmaceuticals, Inc. |
Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
JP2013537423A
(ja)
|
2010-08-17 |
2013-10-03 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
|
|
PT3124610T
(pt)
|
2010-10-28 |
2019-06-14 |
Benitec Biopharma Ltd |
Tratamento do vhb
|
|
EP3467109A1
(en)
|
2011-02-08 |
2019-04-10 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
MX347253B
(es)
|
2011-04-21 |
2017-04-20 |
Ionis Pharmaceuticals Inc |
Modulación de la expresión del virus de hepatitis b (vhb).
|
|
SG194751A1
(en)
|
2011-06-30 |
2013-12-30 |
Arrowhead Res Corp |
Compositions and methods for inhibiting gene expression of hepatitis b virus
|
|
EP2742056B2
(en)
|
2011-08-11 |
2020-06-10 |
Ionis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
|
US10023861B2
(en)
|
2011-08-29 |
2018-07-17 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
|
CA2863253A1
(en)
|
2011-09-07 |
2013-03-14 |
Marina Biotech, Inc. |
Synthesis and uses of nucleic acid compounds with conformationally restricted monomers
|
|
WO2013113326A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
|
|
EP2850092B1
(en)
|
2012-04-09 |
2017-03-01 |
Ionis Pharmaceuticals, Inc. |
Tricyclic nucleic acid analogs
|
|
ES2906023T3
(es)
|
2012-04-10 |
2022-04-12 |
Vib Vzw |
Nuevos marcadores para detectar inestabilidad microsatelital en cáncer y determinar la letalidad sintética con inhibición de la vía de reparación por escisión de bases de ADN
|
|
WO2013159109A1
(en)
|
2012-04-20 |
2013-10-24 |
Isis Pharmaceuticals, Inc. |
Modulation of hepatitis b virus (hbv) expression
|
|
WO2013166264A2
(en)
|
2012-05-02 |
2013-11-07 |
University Of Georgia Research Foundation, Inc. |
Methods for altering virus replication
|
|
KR20240148947A
(ko)
|
2012-07-13 |
2024-10-11 |
웨이브 라이프 사이언시스 리미티드 |
키랄 제어
|
|
EP2890789A1
(en)
|
2012-08-31 |
2015-07-08 |
Aptamir Therapeutics, Inc. |
Mirna modulators of chronic visceral inflammation
|
|
JP6452614B2
(ja)
|
2012-11-15 |
2019-01-16 |
ロシュ イノベーション センター コペンハーゲン エーエス |
オリゴヌクレオチドコンジュゲート
|
|
DK2951305T3
(en)
|
2013-01-30 |
2018-10-29 |
Hoffmann La Roche |
LNA oligonucleotide KULHYDRATKONJUGATER
|
|
PE20152002A1
(es)
|
2013-05-01 |
2016-01-21 |
Isis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion de ttr y vhb
|
|
EP3011035B1
(en)
*
|
2013-06-17 |
2020-05-13 |
The Broad Institute, Inc. |
Assay for quantitative evaluation of target site cleavage by one or more crispr-cas guide sequences
|
|
SG10201908122XA
(en)
|
2013-06-27 |
2019-10-30 |
Roche Innovation Ct Copenhagen As |
Antisense oligomers and conjugates targeting pcsk9
|
|
CN105980615A
(zh)
|
2013-08-28 |
2016-09-28 |
卡里斯生命科学瑞士控股有限公司 |
寡核苷酸探针及其用途
|
|
EP2845607A1
(en)
*
|
2013-09-09 |
2015-03-11 |
University of Vienna |
Antisense oligonucleotides with improved pharmacokinetic properties
|
|
KR102287532B1
(ko)
|
2014-01-30 |
2021-08-11 |
에프. 호프만-라 로슈 아게 |
생분해성 컨쥬게이트를 갖는 폴리 올리고머 화합물
|
|
WO2015113990A1
(en)
|
2014-01-30 |
2015-08-06 |
F. Hoffmann-La Roche Ag |
Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
|
|
EP3143020B1
(en)
|
2014-05-13 |
2019-08-21 |
F. Hoffmann-La Roche AG |
Dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
|
|
GB201408623D0
(en)
*
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
|
TW201610169A
(zh)
|
2014-07-01 |
2016-03-16 |
泰瓦藥品工業有限公司 |
利用哺乳動物及人類細胞進行之格拉雷姆（ｇｌａｔｉｒａｍｅｒ）乙酸鹽相關藥物產品之生物特徵化
|
|
FR3026868B1
(fr)
|
2014-10-02 |
2019-08-16 |
Dav |
Dispositif et procede de commande pour vehicule automobile
|
|
CR20170174A
(es)
|
2014-10-02 |
2017-11-07 |
Protiva Biotherapeutics Inc |
Composiciones y métodos para el silenciamiento de la expresión cénica del virus de la hepatitis b
|
|
CN106795200B
(zh)
|
2014-10-10 |
2020-06-19 |
豪夫迈·罗氏有限公司 |
Galnac亚磷酰胺、其核酸缀合物及其用途
|
|
US9637485B2
(en)
|
2014-11-03 |
2017-05-02 |
Hoffmann-La Roche Inc. |
6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
|
|
JP2017536119A
(ja)
|
2014-11-19 |
2017-12-07 |
ロシュ イノベーション センター コペンハーゲン エーエス |
キラルホスホロチオエート連結を含むｌｎａギャップマーオリゴヌクレオチド
|
|
AU2015349638A1
(en)
*
|
2014-11-21 |
2017-06-15 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
|
EP3234131B1
(en)
|
2014-12-16 |
2020-04-22 |
Roche Innovation Center Copenhagen A/S |
Chiral toxicity screening method
|
|
EP3240537B1
(en)
|
2014-12-30 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
|
|
EP3253871A1
(en)
*
|
2015-02-04 |
2017-12-13 |
Bristol-Myers Squibb Company |
Lna oligonucleotides with alternating flanks
|
|
WO2016128335A1
(en)
|
2015-02-11 |
2016-08-18 |
F. Hoffmann-La Roche Ag |
Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
|
|
WO2016177655A1
(en)
|
2015-05-04 |
2016-11-10 |
F. Hoffmann-La Roche Ag |
Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
|
|
WO2017015175A1
(en)
|
2015-07-17 |
2017-01-26 |
Arcturus Therapeutics, Inc. |
Compositions and agents against hepatitis b virus and uses thereof
|
|
WO2017027350A2
(en)
|
2015-08-07 |
2017-02-16 |
Arrowhead Pharmaceuticals, Inc. |
Rnai therapy for hepatitis b virus infection
|
|
WO2017066712A2
(en)
|
2015-10-16 |
2017-04-20 |
The Children's Medical Center Corporation |
Modulators of telomere disease
|
|
WO2017066796A2
(en)
*
|
2015-10-16 |
2017-04-20 |
The Children's Medical Center Corporation |
Modulators of telomere disease
|
|
TWI840950B
(zh)
*
|
2016-03-14 |
2024-05-01 |
瑞士商赫孚孟拉羅股份公司 |
用於降低pd-l1表現之寡核苷酸
|
|
CN109153697A
(zh)
|
2016-04-14 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
三苯甲基-单-GalNAc化合物及其用途
|
|
EP3472346B1
(en)
*
|
2016-06-17 |
2023-01-18 |
F. Hoffmann-La Roche AG |
Papd5 and papd7 inhibitors for treating a hepatitis b infection
|
|
WO2018001952A1
(en)
|
2016-06-29 |
2018-01-04 |
F. Hoffmann-La Roche Ag |
Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hbv infection
|
|
WO2018059718A1
(en)
|
2016-09-30 |
2018-04-05 |
Rijk Zwaan Zaadteelt En Zaadhandel B.V. |
Peronospora resistance in spinacia oleracea
|
|
CL2020001638A1
(es)
|
2017-10-16 |
2020-10-16 |
Hoffmann La Roche |
Molécula de ácidos nucleicos para la reducción del arnm de papd5 y papd7 en el tratamiento de la infección de la hepatitis b. (divisional solicitud 202000945)
|
|
TW202424191A
(zh)
|
2017-10-16 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子
|
|
BR112020013431A2
(pt)
*
|
2018-01-29 |
2020-12-01 |
F. Hoffmann-La Roche Ag |
processo para a preparação de conjugados de galnac-oligonucleotídeo
|
|
CL2019000945A1
(es)
|
2019-04-09 |
2019-07-12 |
Energy Harvest As |
Dispositivo de válvula rotatoria y sus métodos.
|